BLGO BIOLARGO, INC.
Chemicals & Allied Products · OTC · SEC CIK 880242 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-62.3%
TTM net income YoY-7.8%
TTM EPS YoY—
Revenue 3-yr CAGR-25.8%
Net income 3-yr CAGR—
Margins
Gross margin43.7%
Operating margin-355.4%
Net margin-260.6%
FCF margin—
EBITDA margin-349.9%
Returns
ROE-1,608.5%
ROA-129.8%
ROIC (approx.)—
Asset turnover0.50x
Leverage & solvency
Liabilities / assets165.9%
Debt / equity—
Current ratio0.60x
Interest coverage-14.79x
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.76M | $17.78M |
| Cost of revenue | $4.36M | $9.93M |
| Gross profit | $3.41M | $7.85M |
| R&D expense | $2.59M | $2.88M |
| SG&A expense | $11.77M | $9.30M |
| Operating income | -$14.86M | -$4.33M |
| Interest expense | $540,000 | $71,000 |
| Pretax income | -$15.19M | -$4.35M |
| Income tax | — | $0 |
| Net income | -$11.78M | -$2.40M |
| EBITDA | -$14.71M | -$4.18M |
| EPS (basic) | -0.04 | -0.01 |
| EPS (diluted) | — | — |
| Banking | ||
| Net interest income | -$340,000 | -$33,000 |
| Balance sheet | ||
| Cash & equivalents | $3.88M | $3.55M |
| Receivables | $615,000 | $3.17M |
| Inventory | $310,000 | $330,000 |
| Current assets | $5.11M | $7.14M |
| PP&E, net | $1.64M | $1.74M |
| Total assets | $8.31M | $10.51M |
| Current liabilities | $5.06M | $2.65M |
| Short-term debt | — | $66,000 |
| Long-term debt | $2.08M | $1.08M |
| Total debt | $2.08M | $1.15M |
| Total liabilities | $6.79M | $4.46M |
| Shareholders' equity | $4.04M | $8.85M |
| Net debt | -$1.80M | -$2.40M |
| Cash flow statement | ||
| Operating cash flow | -$8.30M | -$3.21M |
| Investing cash flow | $435,000 | -$1.32M |
| Financing cash flow | $8.22M | $4.44M |
| Depreciation & amortization | $145,000 | $155,000 |
| Stock-based compensation | $2.96M | $2.06M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.